[vc_row][vc_column][vc_column_text] In August 2018, the FDA & European Commission announced the approval of Alnylam Pharmaceutical’s ONPATTRO, a first-of-its-kind RNA interference (RNAi) therapeutic. Evolution Executive’s latest […]
[vc_row][vc_column][vc_column_text] German pharmaceutical company Evotec has expanded its partnership with Scottish artificial intelligence drug design pioneers Exscientia, investing a further €15m in exchange for a minority […]
[vc_row][vc_column][vc_column_text] After a well-documented lull in 2016 and a sluggish start to 2017, the global therapeutic IPO market has started to bounce back in Q2, […]
[vc_row][vc_column][vc_column_text] Healthcare multinational Johnson & Johnson will pay $30B to acquire Swiss drugmaker Actelion in an all-cash deal. Under the conditions of the deal, Actelion will […]